GRAPPA 点对点:生物药物应用于轻度牛皮吗?
Gretchen D Ball1, Hassan Hamade2, Alice B Gottlieb2
1G.D. Ball, BS, H. Hamade, MD, A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; gretchen.ball@einsteinmed.edu.
The Journal of rheumatology
|August 1, 2024
概括
局部疗法是轻度牛皮 (PsO) 的标准,但生物药物可能被认为是有限的PsO与牛皮关节炎或特殊部位的参与. 早期的生物治疗可能会降低牛皮关节炎的风险.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
背景情况:
- 牛皮 (PsO) 根据严重程度 (轻度,中度,严重) 进行分类,使用身体表面积 (BSA) 等措施.
- 局部疗法通常推用于轻度PsO,但生物药物在特定轻度病例中的作用是有争议的.
研究的目的:
- 探索使用局部与生物疗法用于轻度或有限的牛皮的辩论.
- 在轻度的PsO病例中提出支持和反对生物使用的论点,考虑BSA以外的因素.
主要方法:
- 在2023年牛皮和牛皮关节炎研究和评估小组 (GRAPPA) 年会上讨论和提出论点.
- 审查新的数据和现有的治疗方案,以治疗牛皮.
主要成果:
- 在轻度的PsO中,支持生物药物的论点包括牛皮关节炎 (PsA) 的存在和特殊部位的参与 (头皮,脸部,生殖器,指甲等). ) 的情况.
- 新的数据表明,早期治疗有限的PsO可能会降低PsA发展风险.
- 针对轻度PsO的生物制剂的论点强调,有限的BSA与PsA和生活质量影响不应该被归类为轻度,有利于更安全,更低成本的局部治疗.
结论:
- 轻度PsO的定义和适当的治疗策略,包括生物药物,仍然是讨论的领域.
- 新兴的疗法,如roflumilast和tapinarof提供扩大局部选择,特别是在特殊的网站.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:26Psychosis: Goals of Pharmacotherapy
114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114